- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01603420
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Illinois
-
Warrenville, Illinois, United States, 60555
- CDH Proton Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73142
- ProCure Proton Therapy Center
-
-
Virginia
-
Hampton, Virginia, United States, 23666
- Hampton University Proton Therapy Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed prostate adenocarcinoma (within 365 days of randomization.
- High-risk for recurrence as determined by evidence of at least one of the following: Gleason score 8-10, PSA > 20, T state T3.
- Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material: Gleason score must be in the range 2-10. > 6 cores are strongly recommended.
- Clinical stages T1a- T3 N0 M0 as staged by the treating investigator. (AJCC Criteria 7th Ed.-appendix III).
- PSA values < = 50 ng/ml within 90 days prior to randomization. Must be completed prior to biopsy or at least 21 days after prostate biopsy.
- Absolute Neutrophil Count (ANC) > = 1,800 cells/mm³ within 90 days prior to randomization.
- Platelets > = 100,000 cells/mm³ within 90 days prior to randomization.
- Hemoglobin > 10 g/dl within 90 days prior to randomization.
- ALT, AST, and total bilirubin within 1.5 X institutional upper normal limits within 90 days prior to randomization.
- ECOG status 0-1 (appendix II) documented within 90 days of randomization.
- Patient must sign study specific informed consent prior to randomization. Note: consent for legally authorized representative is not permitted.
- Completed all requirements listed in section 4.0 within the specified time frames.
- Able to start treatment within 56 days of randomization.
- At least 18 years old and less than or equal to 75 years of age.
- Men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards.
- Medical oncology consultation prior to randomization and medically approved for chemotherapy treatment per protocol.
Exclusion Criteria:
- Evidence of distant metastasis.
- Pelvic lymph nodes > 1.5 cm in greatest dimension unless the enlarged lymph node is biopsied and negative.
- Prior prostate cancer surgery including but not limited to prostatectomy, hyperthermia and cryosurgery.
- Prior pelvic radiation for their prostate cancer.
- Prior androgen deprivation.
- Severe, active co-morbidity, defined as follows:
- Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed).
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months.
- Myocardial infarction within the last 6 months.
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of randomization.
- Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
- Prior allergic reaction to the drugs involved in this protocol.
- Existing peripheral neuropathy > = grade 2.
- Prior systemic chemotherapy for prostate cancer.
- History of proximal urethral stricture requiring dilatation.
- Major medical, addictive or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up.
- Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Radiation + 24mo luteinizing hormone-releasing hormone (LHRH)
Conformal RT 79.2 Gy(RBE) total dose + 24 months LHRH agonist (androgen suppression).
|
Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
Other Names:
1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
Other Names:
|
Experimental: Radiation + Chemo + 6mo luteinizing hormone-releasing hormone
Conformal RT 79.2 Gy(RBE) total dose + Chemotherapy: Docetaxel 20mg/m2 x every 7 days x 8 weeks followed by 6 months LHRH (androgen suppression).
|
Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
Other Names:
1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
Other Names:
Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 2 - Assessment of Number of Freedom From Failure Events in the Chemotherapy Arm
Time Frame: No failures were reported at the time of study termination (22 months). This outcome was originally written to assess failure at 2 years. However, that end point was not reached.
|
Measurement of Freedom from Failure i.e. the first occurence of clinical failure (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the Phoenix definition (Prostate Specific Antigen [PSA] > = 2 ng/ml over the nadir PSA discounting bounces per the investigators discretion), or the start of salvage therapy including androgen deprivation. This study was terminated prior to the time frame of 2 years being reached. Therefore, this outcome was assessed at time of study closure (22 months). |
No failures were reported at the time of study termination (22 months). This outcome was originally written to assess failure at 2 years. However, that end point was not reached.
|
Phase 2 - Assessment of Number of Freedom From Failure Event Comparing Chemotherapy Arm to Standard Treatment Arm
Time Frame: at 5 years
|
This endpoint will be examined if decision is made to not move forward with phase 3 study. This study was terminated prior to a decision being made about moving on to a phase 3 study. Therefore, this outcome was not assessed. |
at 5 years
|
Phase 2 - Cumulative Number of Incidences of Grade 3 or Higher Adverse Events.
Time Frame: 2 years
|
Assessment will be performed using CTCAE v4 criteria. This study was terminated prior to the time frame of 2 years being reached. Therefore, this outcome was assessed at time of study closure (22 months). |
2 years
|
Phase 3 - Assessment of the Number of Freedom From Failure (FFF) Events Comparing the Chemotherapy Arm to the Standard Treatment Arm.
Time Frame: at 5 years
|
The events for FFF will be the first occurence of clinical failure (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the Phoenix definition (PSA > = ng/ml over the nadir PSA discounting bounces per the investigators discretion), or the start of salvage androgen deprivation. This study was terminated prior to a decision being made about moving on to a phase 3 study. Therefore, this outcome was not assessed. |
at 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Number of Grade 2 or Higher Genitourinary (GU) and Gastrointestinal (GI) Adverse Events
Time Frame: at 6 months
|
Assessment will be performed using CTCAE v 4 criteria.
|
at 6 months
|
Assessment of Number of GI and GU Adverse Events
Time Frame: at 3 years
|
Descriptive measurements of frequency will be compiled. This study was terminated prior to the time frame of 3 years being reached. Therefore, this outcome was not assessed. Data were collected on toxicities up until study closure at 22 months. However, this timepoint was not indicated as a secondary objective in the protocol. Therefore, data was not analyzed at time of study closure. |
at 3 years
|
Assessment of Total Number of Local/Distant Failures
Time Frame: at time of study closure (22 months)
|
The total number of local/distant failures will be assessed.
|
at time of study closure (22 months)
|
Assessment of Impotence by Summation of Relative Scores for Sexual Function From the EPIC Quality of Life Instrument.
Time Frame: Up to 10 years
|
unable to assess due to lack of data
|
Up to 10 years
|
Assessment of Total Number of Salvage Androgen Deprivation Use With Comparison of Arms.
Time Frame: At study closure (22 months)
|
The total number of subjects with salvage androgen deprivation use will be assessed.
|
At study closure (22 months)
|
Assessment of Total Number of Survival Events With Comparison of Group Arms
Time Frame: at study closure (22 months)
|
The number of deaths in both arms will be assessed.
|
at study closure (22 months)
|
Assessment of Total Number of Biochemical Failure Events
Time Frame: at study closure (22 months)
|
The number of biochemical failure events will be assessed on both arms.
|
at study closure (22 months)
|
Assessment of Quality of Life - Summation of Relative Scores From the EPIC Instrument.
Time Frame: Up to 10 years
|
unable to assess due to lack of data
|
Up to 10 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Carlos Vargas, MD, Proton Collaborative Group
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protective Agents
- Estrogens
- Micronutrients
- Vitamins
- Antioxidants
- Anabolic Agents
- Docetaxel
- Hormones
- Ascorbic Acid
- Androgens
- Prolactin Release-Inhibiting Factors
- Methyltestosterone
- Estrogens, Conjugated (USP)
Other Study ID Numbers
- GU004-11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Luteinizing hormone-releasing hormone (LHRH)
-
Rabin Medical CenterFerring PharmaceuticalsCompletedCardiovascular Diseases | Prostatic NeoplasmsIsrael
-
Lawson Health Research InstituteTerminated
-
NRG OncologyNational Cancer Institute (NCI)SuspendedProstate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8Canada, United States
-
Tianjin Medical University Cancer Institute and...Peking University First Hospital; The Affiliated Nanjing Drum Tower Hospital... and other collaboratorsUnknownStage IV Prostate CancerChina
-
University of British ColumbiaUnknownProstate CancerCanada
-
US Department of Veterans AffairsCompletedHypogonadism | Spinal Cord InjuryUnited States
-
National Center for Research Resources (NCRR)University of TexasCompleted
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)CompletedProstate CancerUnited States, Canada
-
Sidney Kimmel Cancer Center at Thomas Jefferson...SanofiCompleted
-
Tianjin Medical University Cancer Institute and...Peking University First Hospital; The Affiliated Nanjing Drum Tower Hospital... and other collaboratorsUnknownStage III Prostate CancerChina